The company removed experimental drugs for Alzheimer’s, migraine and pain from its pipeline to focus more resources on “core ...

In addition, Eisai must conduct a post-authorization safety study, including setting up a patient registry for the European Union. Now each European country must set its own rules for access and ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

The European Commission has approved Eisai and Biogen's Leqembi in Alzheimer's disease. Kyowa Kirin has finished the build-out of a Japanese biologics plant. And more. The Trump administration has ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more ...

Copyright 2025 The Associated Press. All Rights Reserved. Copyright 2025 The Associated Press. All Rights Reserved. The Biogen Inc., headquarters is pictured on March ...

(RTTNews) - Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced that the European Commission has granted the amyloid-beta (A) monoclonal antibody Leqembi (lecanemab) Marketing ...

Eisai is spearheading development and regulatory rollout. Credit: PeopleImages.com – Yuri A/Shutterstock. Eisai and Biogen have received marketing authorisation (MA) from the European Commission (EC) ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) ...

At the root of the question on the future of compounded GLP-1RAs is whether widespread shortages will occur again. Even after the shortages for both drugs ended as per the FDA, the American Society of ...